Moreover, in lymphomas, CIITA has been reported to be a recurrent fusion partner of the programmed death-ligands CD274/PD-L1 and CD273/PD-L2, leading to the downregulation of HLA class II genes and the upregulation of PD-L1 and PD-L2 (50). The gene discussed is PDCD1LG2; the disease is lymphoma.